All In Biotech

Investigational drug · Phase 3

Sasanlimab

Also called: PF-06801591

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-muscle Invasive Bladder Cancer.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

23

Any phase or sponsor naming "Sasanlimab"

First trial start

2019

Dec 30, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Sasanlimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-muscle Invasive Bladder Cancer

Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Sasanlimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 25 on PubMed

Also in development for Non-muscle Invasive Bladder Cancer

  • BCGPhase 38 trials

    ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis

  • Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

  • TARA-002Phase 33 trials

    Protara Therapeutics · Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

  • EG-70Phase 21 trial

    enGene, Inc. · Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.